Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) have been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $23.67.

A number of research firms have recently issued reports on TVTX. Guggenheim increased their price objective on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Piper Sandler boosted their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $9.00 to $27.00 in a report on Monday, October 21st. Wedbush lifted their price objective on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Finally, HC Wainwright lowered their target price on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, September 27th.

Insider Activity

In other news, CAO Sandra Calvin sold 12,090 shares of Travere Therapeutics stock in a transaction on Monday, November 25th. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00. Following the sale, the chief accounting officer now directly owns 54,927 shares in the company, valued at $1,005,164.10. The trade was a 18.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.75% of the stock is currently owned by corporate insiders.

Institutional Trading of Travere Therapeutics

A number of large investors have recently added to or reduced their stakes in TVTX. CWM LLC grew its position in shares of Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after acquiring an additional 3,065 shares during the period. DRW Securities LLC purchased a new position in Travere Therapeutics in the second quarter valued at approximately $95,000. Quarry LP bought a new position in Travere Therapeutics during the third quarter valued at $105,000. Forefront Analytics LLC increased its position in Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after buying an additional 1,237 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in shares of Travere Therapeutics in the second quarter valued at $117,000.

Travere Therapeutics Price Performance

TVTX stock opened at $18.86 on Monday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The company’s fifty day simple moving average is $18.12 and its 200 day simple moving average is $13.82. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $20.33. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -4.15 and a beta of 0.69.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. During the same quarter last year, the firm posted ($1.17) earnings per share. The firm’s revenue was up 69.6% on a year-over-year basis. On average, analysts expect that Travere Therapeutics will post -3.94 earnings per share for the current year.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.